{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:05:33Z","timestamp":1768266333426,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.cmi.2016.07.025","type":"journal-article","created":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T03:17:33Z","timestamp":1469935053000},"page":"891.e5-891.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia"],"prefix":"10.1016","volume":"22","author":[{"given":"S.","family":"Imbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Castain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Palous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Vezinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Langeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Monsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fekkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2016.07.025_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijantimicag.2011.02.016","article-title":"Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the sentry antimicrobial surveillance program (2008\u20132009)","volume":"38","author":"Pfaller","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2016.07.025_bib2","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1128\/AAC.03255-14","article-title":"Role of fks mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance","volume":"58","author":"Pham","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2016.07.025_bib3","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s10096-014-2096-9","article-title":"Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?","volume":"33","author":"Fekkar","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2016.07.025_bib4","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1128\/JCM.06112-11","article-title":"Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata","volume":"50","author":"Pfaller","year":"2012","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2016.07.025_bib5","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1128\/AAC.49.8.3264-3273.2005","article-title":"Specific substitutions in the echinocandin target fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates","volume":"49","author":"Park","year":"2005","journal-title":"Antimicrob Agents Chermother"},{"key":"10.1016\/j.cmi.2016.07.025_bib6","doi-asserted-by":"crossref","first-page":"e1002718","DOI":"10.1371\/journal.ppat.1002718","article-title":"Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata","volume":"8","author":"Singh-Babak","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2016.07.025_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/infdis\/jir351","article-title":"Fitness and virulence costs of Candida albicans fks1 hot spot mutations associated with echinocandin resistance","volume":"204","author":"Ben-Ami","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.07.025_bib8","first-page":"32","article-title":"Antifungal resistance does not necessarily affect Candida glabrata fitness","volume":"26","author":"Borghi","year":"2014","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2016.07.025_bib9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1128\/EC.00215-08","article-title":"Uneven distribution of mating types among genotypes of Candida glabrata isolates from clinical samples","volume":"8","author":"Brisse","year":"2009","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.cmi.2016.07.025_bib10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/AAC.01486-12","article-title":"Elevated chitin content reduces the susceptibility of Candida species to caspofungin","volume":"57","author":"Walker","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2016.07.025_bib11","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/iai.64.8.3244-3251.1996","article-title":"Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies","volume":"64","author":"Kurtz","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2016.07.025_bib12","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1128\/AAC.02189-13","article-title":"Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin","volume":"58","author":"Bizerra","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2016.07.025_bib13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/jac\/dku518","article-title":"Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia","volume":"70","author":"Cho","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16302634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16302634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:21:43Z","timestamp":1761117703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X16302634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1198743X16302634"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.07.025","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2016.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}